Where to buy Asciminib

Asciminib (Asciminib) is a tyrosine kinase inhibitor used to treat patients with Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+CML). Acts by specifically targetingABL myristoyl pocket (STAMP). Aceminib is the first STAMP inhibitor of its kind and makes important progress in addressing tyrosine kinase inhibitor (TKI) resistance in patients with chronic myelogenous leukemia who develop intolerance or inadequate response after at least two TKI treatments.

Aceminib is indicated for the treatment of adult patients, including Philadelphia chromosome-positive chronic myeloid leukemia (Ph+CML) in chronic phase (CP), who have been previously treated with two or more tyrosine kinase inhibitors (TKIs). This indication is approved under accelerated approval based on major molecular response (MMR). Continued approval for this indication may be dependent on verification and description of clinical benefit in confirmatory trials. AximiniIndications also include Ph+CML in CP with T315I mutation.

The original drug Aceminid has not yet been launched in China, so it cannot be included in medical insurance. Patients cannot yet purchase the drug through relevant domestic channels. The original drug Aceminid sold overseas is currently very expensive. Generic drugs of Asiminil are also produced and marketed overseas, and their drug ingredients are basically the same as those of the original drug. For example, the price of 40mg*60 tablets produced by a Laos pharmaceutical factory may be more than 4,000 yuan per box (the price may fluctuate due to exchange rate effects), and the price is relatively cheap. For more drug information and specific prices, please consult Yaode’s medical consultant.